Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Stoke Therapeutics Inc shares valued at $228,543 were sold by Ticho Barry on May 02 ’25. At $10.03 per share, Ticho Barry sold 22,790 shares. The insider’s holdings dropped to 33,998 shares worth approximately $0.31 million following the completion of this transaction.
Also, Ticho Barry sold 3,841 shares, netting a total of over 38,410 in proceeds. Following the sale of shares at $10.00 each, the insider now holds 56,788 shares.
Before that, BARUCH S. TICHO had added 34,847 shares to its account. In a trade valued at $340,107, the Officer bought Stoke Therapeutics Inc shares for $9.76 each.
As published in their initiating research note from Chardan Capital Markets on December 20, 2024, Stoke Therapeutics Inc [STOK] has been a Buy and the price target has been revised to $24. As of March 26, 2024, TD Cowen has increased its “Market perform” rating to a “an Outperform” for STOK.
Analyzing STOK Stock Performance
During the last five days, there has been a drop of approximately -8.31%. Over the course of the year, Stoke Therapeutics Inc shares have dropped approximately -17.95%. Shares of the company reached a 52-week high of $12.98 on 02/05/25 and a 52-week low of $5.35 on 04/09/25. A 50-day SMA is recorded $8.06, while a 200-day SMA reached $11.33.
Support And Resistance Levels for Stoke Therapeutics Inc (STOK)
According to the 24-hour chart, there is a support level at 8.63, which, if violated, would cause prices to drop to 8.20. In the upper region, resistance lies at 9.36. The next price resistance is at 9.66. RSI (Relative Strength Index) is 54.73 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.57, which suggests the price will decrease in the coming days. Percent R is at 40.53%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
